
Short answer: women can take SARMs in the sense that women were included in some trials, but none is approved, and the main risk for women is the very thing SARMs do: switch on the androgen receptor. Women make far less testosterone than men, so even a modest androgen effect can cause a deeper voice, more facial and body hair, clitoral enlargement and missed periods. Studies of women using anabolic steroids show these changes can be permanent, especially the voice.
Trials that included women tested ostarine in healthy postmenopausal women and in women with breast cancer, LGD-4033 in older adults after hip fracture, and RAD-140 in women with advanced breast cancer. None was in young, healthy women training for muscle or fat loss. For a compound-by-compound comparison, see best SARMs for women.
What studies in women found
| Compound | Women studied | Findings |
|---|---|---|
| Ostarine | Postmenopausal women and older men, 86 days, 0.1–3 mg/day | Lean mass +1.3 kg vs placebo on 3 mg; HDL down 17–27% on 1–3 mg |
| Ostarine | 136 postmenopausal women with AR+/ER+ advanced breast cancer, 9 or 18 mg/day | Clinical benefit in about 3 in 10; grade 3/4 drug-related side effects in 8–16%, most often raised liver enzymes |
| RAD-140 | 22 postmenopausal women with ER+ advanced breast cancer, 50–150 mg/day | AST rose in 59% and ALT in 45%; serious liver-enzyme rises in 23%; SHBG fell in every patient measured |
| LGD-4033 | Adults over 65 after hip fracture (men and women), 12 weeks | Lean mass 4.75–9.08% above placebo |
All of these were older or ill women under medical supervision. None of the trials was designed to look for masculinizing effects in young women.
Four myths about SARMs for women
Myth 1: Women only use SARMs to lose fat
This myth probably propagated since many have this image in their head on what a woman should look like and chunky isn’t a word among them.
There is nothing wrong with you if you’re a woman that wants to build muscle and bulk up. You’re still just as sexy and valid as those skinny models they plaster all over our cosmetics.
As more and more women join bodybuilding and use SARMs, it is increasingly becoming clear that building and maintaining muscle mass, increasing strength, lifting more weights and improving their personal bests is among the top priorities for women.
Whatever the goal, the risks below are the same.
Myth 2: Women handle SARMs better than men
A common claim online is that women “handle SARMs better than men” and can take any SARM as long as they watch the dose. There is no evidence for that. Women start from much lower androgen levels, so the same drug produces a larger relative androgen effect. The compounds marketed as strongest, such as RAD-140, YK-11 and S-23, have either no human data at all or, in RAD-140’s case, a trial in women where liver-enzyme rises were common.
Women’s own accounts show how this plays out. In interviews with women who used anabolic steroids, many were unprepared for masculinizing effects; a deepened voice was the hardest to live with, because it could not be undone or hidden. Online, women describe the same with SARMs, including voice changes after raising their LGD-4033 dose.
Myth 3: There is a safe “female dose”
There isn’t. No trial has tested SARMs for muscle or fat loss in young women, so there is no evidence-based dose; rules of thumb such as “take half the male dose” are guesses. The doses studied in healthy postmenopausal women were 0.1–3 mg/day of ostarine. For androgens in general, a 2025 review found voice changes were dose- and duration-dependent and potentially irreversible. Lower and shorter means less risk, not no risk.
Myth 4: Women don’t get suppressed, so they don’t need to worry about hormones
Women don’t have testes, but the same brain signals (LH and FSH) drive the ovaries, and androgens disrupt that cycle. Missed or stopped periods are among the effects women report with anabolic steroids, and SARMs act on the same receptor. PCT has never been studied in women after SARMs. Irregular or absent periods, or any masculinizing change, are reasons to stop and see a doctor, who can check hormones and rule out other causes.

Side effects women report
Short-term effects users describe include acne, oily skin, mood changes, poor sleep and changes in the menstrual cycle. Longer-term and more serious risks are the masculinizing effects above, lower HDL cholesterol, and liver injury, which has been reported in case studies with ostarine, LGD-4033 and RAD-140 products. Product quality is a risk too: in a 2017 test of 44 SARM products bought online, only 52% contained a SARM, and 39% contained another unapproved drug. See SARMs side effects and do SARMs cause acne?
What about cardarine and MK-677?
These two are often suggested to women because they are not SARMs and do not act on the androgen receptor, so masculinizing effects are not expected. They have their own risks: cardarine’s development was stopped after cancers in long-term animal studies (female rats on every dose died earlier, often of uterine cancer), and MK-677 raised blood sugar, appetite and prolactin in trials. See the cardarine and MK-677 fact sheets.
If you are still considering SARMs
- Read the evidence for each compound in the SARMs database first.
- Get baseline bloodwork (lipids, liver enzymes, hormones); see the bloodwork guide.
- Stop at the first masculinizing sign: voice change, new facial hair, clitoral changes or missed periods.
- Only buy from a shop that publishes batch-specific, independent lab tests. Sarmguide’s pick is SwissChems; see our SwissChems review and how to read a COA in the lab tests guide.
- Do not use them if pregnant or trying to conceive; no SARM has been tested in pregnancy.
Conclusion
Women have been included in SARM trials, but only older or ill women, and none of those trials looked for the effect that matters most to women: masculinization. Because SARMs work through the androgen receptor, there is no reliably safe SARM or dose for women, and some changes may not reverse. If you are weighing it anyway, start with the evidence, get tested and stop at the first sign of change. Related: best SARMs for women · ostarine before and after · start here
Frequently asked questions
Can women take SARMs?
None approved; masculinizing riskEvidence: Trial
No SARM is approved for anyone; women were included in trials of ostarine, LGD-4033 and RAD-140, but only older or ill women. Because SARMs act on the androgen receptor, masculinizing effects are the main risk for women.
Can females take RAD-140?
Not shown to be safeEvidence: Trial
In its only trial, in women with advanced breast cancer, AST rose in 59% and ALT in 45% of patients. It is one of the strongest androgens sold as a SARM and carries a high risk of masculinizing effects.
Do SARMs cause virilization in women?
They canEvidence: Human data
They act on the androgen receptor. With androgens, women report a deeper voice, more body hair, clitoral enlargement and missed periods, and a review found voice changes may be irreversible.
Do women need PCT after SARMs?
Never studied in womenEvidence: Limited
PCT has never been studied in women after SARMs. Androgens can disrupt the menstrual cycle; irregular periods or masculinizing signs are reasons to stop and see a doctor.
Do SARMs give you estrogen?
No conversion to estrogenEvidence: Human data
SARMs do not convert to estrogen the way testosterone does. In women, the concern is the opposite: too much androgen effect.
How long do SARMs stay in your body?
Depends on the compoundEvidence: Human data
Anti-doping studies found a single tiny dose of ostarine in urine for up to 9 days, RAD-140 for up to 29 days, and LGD-4033 breakdown products for over 40 days.
Will one cycle of SARMs hurt me?
It canEvidence: Human data
Masculinizing effects of androgens depend on dose and duration, but some women report changes within weeks, and voice changes may not reverse. Liver injury case reports also involved single courses.
Sources
- The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial
- Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial
- A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer
- ClinicalTrials.gov NCT02578095: Acute Hip Fracture Study in Patients 65 Years or Greater (VK5211), posted results
- Voice Change as a Result of Androgen Supplementation in Cisgender Women: A Scoping Review
- Anabolic-androgenic steroid use among women - A qualitative study on experiences of masculinizing, gonadal and sexual effects
- Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet
- Rat carcinogenicity study with GW501516, a PPAR delta agonist (Geiger et al., The Toxicologist 2009, abstract 895)
- Elimination profiles of microdosed ostarine mimicking contaminated products ingestion
- Human In Vivo Metabolism and Elimination Behavior of Micro-Dosed Selective Androgen Receptor Modulator RAD140 for Doping Control Purposes
- Investigations into the elimination profiles and metabolite ratios of micro-dosed selective androgen receptor modulator LGD-4033 for doping control purposes